Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE Healthcare Technologies Inc (GEHC) delivers innovative medical technologies that shape global healthcare through advanced imaging, diagnostics, and patient care solutions. This page provides direct access to official company announcements, financial disclosures, and strategic developments.
Investors and industry professionals will find a centralized repository of GEHC news, including earnings reports, product launches, regulatory updates, and partnership announcements. All content is sourced from verified channels to ensure accuracy and timeliness.
Regular updates cover GEHC's advancements in medical imaging systems, AI-driven diagnostics, and healthcare digitization trends. Bookmark this page to monitor the company’s progress in addressing complex clinical challenges while maintaining compliance with global regulatory standards.
GE HealthCare (Nasdaq: GEHC) announced FDA Premarket Authorization for Pristina Recon DL, a deep learning 3D mammography reconstruction application that enhances image sharpness, reduces artifacts, and preserves patient dose. The technology uses two sequential deep learning models plus iterative reconstruction and NVIDIA RTX acceleration to deliver fast, high-fidelity DBT images in the exam room. Clinical validation cited a 99.1% radiologist preference for overall image quality and improved detection of microcalcifications and masses. The feature is upgradable on Pristina Via and supports workflow and patient‑experience improvements.
GE HealthCare (Nasdaq: GEHC) introduced Genesis™ Radiology Workspace, a cloud-first radiology solution built to unify the user experience, streamline workflows, and enable diagnosticians to read from virtually anywhere.
The platform centers on Genesis™ View (510(k) pending; not available for sale in the United States), a zero-footprint viewer that offers high-performance 2D/3D visualization, embedded AI tools, FHIRcast interoperability, and direct access to Advanced Visualization apps. The suite integrates with GE HealthCare’s Genesis cloud portfolio and will be shown at RSNA 2025 (Nov. 30–Dec. 4) in Chicago, booth 7334.
GE HealthCare (Nasdaq: GEHC) declared a cash dividend of $0.035 per share for the fourth quarter of 2025. The dividend is payable on February 13, 2026 to shareholders of record as of January 9, 2026.
GE HealthCare (NYSE:GEHC) announced on November 24, 2025 the submission of a 510(k) to the U.S. FDA for Photonova™ Spectra, a next‑generation photon‑counting CT (PCCT) system built on GE HealthCare’s proprietary Deep Silicon detector technology. Photonova Spectra offers 8‑bin energy resolution, up to 50x more data versus conventional CT, a 0.23s rotation speed, wide detector coverage and UHD spectral imaging designed for neurology, oncology, musculoskeletal, thoracic and cardiac exams. The system is 510(k)‑pending, not CE marked and not available for sale in the U.S., Europe, Canada or other regions. GE HealthCare highlights NVIDIA partnership for accelerated computing and AI‑enabled reconstruction to support on‑demand spectral images and a one‑scan workflow.
GE HealthCare (Nasdaq: GEHC) agreed to acquire Intelerad for $2.3 billion in cash, aiming to create a cloud-first, AI-enabled enterprise imaging platform across inpatient and outpatient settings.
The deal is expected to close in H1 2026, accelerate GE HealthCare’s SaaS and recurring-revenue mix, and support the company’s goal to triple cloud-enabled offerings by 2028.
Intelerad is forecast to deliver ~$270 million revenue in the first full year (≈90% recurring) and an adjusted EBITDA margin >30%; GEHC expects immediate top-line and EBIT margin accretion, short-term slight EPS dilution due to financing, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) announced that Cardiovascular Associates of America (CVAUSA) plans to expand use of FDA‑approved PET radiotracer Flyrcado (flurpiridaz F 18) across ~25 sites after a successful two‑week, 21‑patient pilot at Cardiovascular Medicine in Davenport, Iowa.
The network performs about 85,000 cardiac PET procedures annually, and GE highlighted new distribution support with CDL Nuclear Technologies and inclusion of flurpiridaz F 18 in a co‑published international procedure standard for cardiac PET MPI.
GE HealthCare (Nasdaq: GEHC) management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 am GMT / 4:30 am ET / 3:30 am CT.
CFO Jay Saccaro will discuss business strategy and growth opportunities and will address recent questions about a competitor’s FDA approval of an X-ray contrast product; GE HealthCare does not expect that approval to have a material impact on its Pharmaceutical Diagnostics business. A live webcast will be available on the company investor website at the listed date and time.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 am GMT (4:30 am ET/3:30 am CT).
A live webcast will be available via the company's investor events page at https://investor.gehealthcare.com/news-events/events on the listed date and time.
GE HealthCare (Nasdaq: GEHC) reported third-quarter 2025 results for the period ended September 30, 2025. Revenues were $5.1 billion, up 6% reported and 4% organic year‑over‑year, with total company orders +6% organic and a book‑to‑bill of 1.06. Net income attributable to GE HealthCare was $446 million; diluted EPS was $0.98 and Adjusted EPS was $1.07. Adjusted EBIT margin was 14.8% and free cash flow was $483 million. The company raised the lower end of full‑year 2025 Adjusted EPS guidance to a range of $4.51 to $4.63 and reaffirmed other metrics while noting approximately $265 million of tariff impact to Adjusted EBIT and $0.45 to Adjusted EPS.
GE HealthCare (Nasdaq: GEHC) announced CE mark clearance for its new Carevance patient monitor on October 21, 2025, enabling initial commercial access in Europe.
Carevance adds Cardiac Output Insights — a non-invasive, on-device hemodynamic view that provides real-time graphical support for perioperative hypotension management without extra hardware or invasive catheters. The platform uses proven algorithms and validated vital-sign parameters and includes the EK-Pro algorithm, which the company says can reduce false ECG alarms by up to 92%. Carevance will be showcased at ESICM in Munich, Oct 25-29, 2025.
FAQ
What is the current stock price of Ge Healthcare Technologies (GEHC)?
What is the market cap of Ge Healthcare Technologies (GEHC)?
